Healthcare Industry News: female sexual dysfunction
News Release - July 18, 2011
BioSante Pharmaceuticals Announces Management Team AdditionsLINCOLNSHIRE, Ill.--(Healthcare Sales & Marketing Network)-- BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX ), today announced the appointment of Sandra Croak-Brossman, MS, Ph.D., as Vice President, Regulatory Affairs and Quality Assurance, and Patricia M. Adams, MS as Vice President, Human Resources. Dr. Croak-Brossman assumed this new role effective today. Ms. Adams assumed her new role effective in May 2011.
Dr. Croak-Brossman joins BioSante with over 24 years of experience in the pharmaceutical industry. She has held a variety of regulatory positions and has led operations at both a U.S. and global level. Dr. Croak-Brossman’s work experience includes positions at Boehringer Ingelheim, Pfizer and Abbott Laboratories. Importantly, while at Pfizer, Dr. Croak-Brossman was the worldwide regulatory lead for Viagra®. Her experience as a regulatory lead in the sexual dysfunction therapeutic market makes her uniquely qualified to manage regulatory projects as BioSante progresses towards the NDA submission for LibiGel® (testosterone gel). Dr. Croak-Brossman earned her MS and Ph.D. in Quantitative Genetics and Animal Breeding from Purdue University and conducted her Post-Doctoral Fellowship at Cornell University.
Ms. Adams has over 20 years of experience in the pharmaceutical industry. From 2009 through May 2011, Ms. Adams was with Lundbeck Inc. (the U.S. subsidiary of H. Lundbeck A/S based in Copenhagen, Denmark) where she most recently served as the Vice President of Human Resources. Prior to joining Lundbeck, Ms. Adams was employed by Takeda Pharmaceuticals North America from 1998 – 2009. While at Takeda, Ms. Adams held positions of increasing responsibility in both Human Resources and Sales Operations and created foundational policies and procedures to support the launch of Takeda’s North American headquarters. Ms. Adams’ previous work experiences also include time at both TAP Pharmaceuticals and Abbott Laboratories. Ms. Adams earned her MS in Human Resources from Loyola University Chicago and her Senior Professional in Human Resources certification from The Human Resources Certification Institute.
“We are very pleased to have both Sandra Croak-Brossman and Patricia Adams joining us at this exciting time for BioSante,” said Stephen M. Simes, BioSante’s president and chief executive officer. “Sandy’s experience and expertise, particularly in leading Pfizer’s Viagra to an FDA approval, will be invaluable in view of the excellent progress we have made in the development of LibiGel for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product. Patty has a clear vision for where HR needs to go and how to help BioSante recruit, retain and develop the best talent in the pharmaceutical industry. We remain dedicated to our objective of maximizing stockholder value and believe Sandy and Patty will be integral to this endeavor.”
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante’s plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s licensees or sublicensees; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Source: BioSante Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.